Date: Saturday, June 11, 2016
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
- Molecular Marker Strategies Supporting the Novartis US92 Study- A Discovery Study of Protein Biomarkers for Kidney Function (eGFR) and Acute Rejection in Serum from Renal Transplant Patients
- Serum Changes in FGF23 and Biochemical Biomarkers of Bone Mineral Disorder in Children after Renal Transplantation
Kidney transplant recipients (KTR) have an increased risk for cardiovascular events, graft failure, and death. It is unknown whether serum inflammatory biomarkers correlate with eGFR status. Aim: To determine pro- and anti-inflammatory cytokine serum levels in KTR and previous renal donors (RD) with different eGFR stage. Methods: Exploratory, observational and cross-sectional study conducted in 125 KTR and 78 RD (1989-2014). KTR KDIGO eGFR were: Stage 1, n=22; Stage 2, n=60; Stage 3, n=43, under chronic immunosuppression (Tacrolimus: 90 %, Cyclosporine: 8%, MMF: 90%, Prednisone 99%). RD KDIGO eGFR Stage 1, n=15; Stage 2, n=35; Stage 3, n=28. Serum levels of IL-2, IL-4, IL-8, IL-17A, IL-22, Interferon γ and TGF-β were measured by ELISA. Results: Demographic characteristics and cytokine serum levels are summarized in Table. Cytokine pattern in KTR with eGFR from stage 1 to 3 was significantly increased vs. renal donors at the same renal function (Table).
|Variable||KTR (n=125)||RD (n=78)||P|
|Age (yrs) mean±SD (range)||36.8±12.9 (20-75)||45.1±13 (21-77)||â€¹0.001|
|F-U (months)||33.9±14.6 (11-96)||57.6±55.6 (12-240)||0.19|
|IL-22 (ng/mL) mean±SD (range)||0.91±2.8 (0.0-23.74)||0.13±0.24 (0.05-1.70)||â€¹0.001|
|IL-17A (pg/mL) mean±SD (range)||4.13±18.77 (0.0-212.59)||0.62±0.67 (0-32.03)||â€¹0.07|
|IL-8 (pg/mL) mean±SD (range)||154.85±1014.33 (0.00-12000)||25.56±58.14 (0.00-396.38)||0.001|
|IL-4 (pg/mL) mean±SD (range)||73.31±155.79 (0.00-1048.8)||30.36±24.64 (4.66-107.29)||0.003|
|IL-2 (ng/mL) mean±SD (range)||0.30±1.32 (0.00-14.00)||1.80±3.5 (0.00-20.4)||0.001|
|Interferon Î³ (ng/mL) mean±SD (range)||5.10±5.01 (0.00-15.80)||0.28±0.85 (0.00-4.51)||0.001|
|TGFÎ² (ng/mL) mean±SD (range)||0.44±0.99 (0.00-9.92)||0.011±0.024 (0.00-0.095)||0.001|
Conclusions: KTR in “stable conditions” are inflamed notwithstanding of chronic immunosuppressive therapy. The only viable explanation for this cytokine increased pattern is the allograft itself. It is tempting to speculate that the peripheral inflammation documented might confer a permanent increased cardiovascular risk despite the excellent renal function stage 1 and 2 eGFR represents to KTR.
CITATION INFORMATION: Ramirez J, Cuevas E, Furuzawa J, Morales-Buenrostro L, Lopez-Cervantes M, Alberu J. Serum Inflammatory Biomarkers in Kidney Transplant Recipients and Renal Donors. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Ramirez J, Cuevas E, Furuzawa J, Morales-Buenrostro L, Lopez-Cervantes M, Alberu J. Serum Inflammatory Biomarkers in Kidney Transplant Recipients and Renal Donors. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/serum-inflammatory-biomarkers-in-kidney-transplant-recipients-and-renal-donors/. Accessed March 3, 2021.
« Back to 2016 American Transplant Congress